AURORA, ON- Helix BioPharma Corp. , a biopharmaceutical providers establishing treatment prospects for prevention and remedy for disease, these days announced that it will file an application 15F with all the usa Securities and trade charge (the “SEC”) making use of the aim of ending registration of their popular shares under part 12(g) associated with the U . S . investments trade work of 1934, as revised (the “Exchange function”) and terminating their reporting duties for all those of the authorized investments under area 15(d) regarding the swap Act.

As earlier launched, Helix has actually voluntarily delisted the usual carries from the NYSE MKT. On June 9, 2012, Helix submitted a Form 25 employing the SEC to trigger the voluntary delisting, which turned into successful on July 19, 2012. On July 18, 2012, Helix submitted a Post-Effective modification to the enrollment report on kind F-10 using SEC, doing away with from registration all unsold investments.

Upon making the kind 15F submitting, Helix’s revealing obligations employing the SEC, including its obligation organizing stories on Form 20-F and furnish report on kind 6-K, will right away getting dangling. Helix needs that its revealing requirements will likely be ended efficient three months after completing the contour 15F by using the SEC. Helix is definitely up-to-date with its reporting requirements beneath swap function.

Helix’s usual percentage continues to trading the Toronto area Stock Exchange beneath ticker mark “HBP” along with service will continue to document vital research with Canadian Securities directors at www.sedar.com, and creating economic and other material info on their web site at www.helixbiopharma.com.

About Helix BioPharma Corp. Helix BioPharma Corp. is definitely a biopharmaceutical service devoted to the field of cancer tumors therapy. The business try earnestly developing ground breaking equipment for your avoidance and remedy for cancer tumors determined its proprietary technologies. Helix’s items growth projects add its novel L-DOS47 unique pill prospect as well as Topical Interferon Alpha-2b. Helix happens to be listed on the TSX and FSE under the expression “HBP.”

Forward-Looking Statements and issues and Uncertainties This reports launch is made up of specific forward-looking assertions and critical information (together, “forward-looking statements”) around the purpose of applicable Canadian and U.S. investments legislation, including, without limitation, forward-looking comments relating to Helix’s purpose to eliminate their SEC revealing duties. Forward-looking words, which can be recognized by terminology such as, without issue, “will” and “expects” as well as other equivalent construction, tend to be designed to give information regarding procedures’s latest ideas and objectives pertaining to foreseeable operations.

Although Helix feels the goals reflected in such forward-looking claims tend to be sensible, this assertions involve threats and concerns that can create actual results or happenings to differ materially from those predicted without assurance is generally seeing that these needs will be came to the realization, and excessive reliance should not be added to such records. Chances elements that would bring real listings or competition to are different materially through the forward-looking comments put, without limitation, the danger your cancellation of stating commitments might not take place regarding schedule awaited by Helix. Absolutely clear on these issues and concerns, and others affecting they, are usually more totally explained in Helix’s gross Report on version 20-F, such as within the headings “Forward-Looking words” and “3.D possibility issues,” submitted by using the SEC at www.sec.gov along with the Canadian Securities managers at www.sedar.com (with each other, the “Helix possibility Things”). Several content elements or presumptions are applied in deciding to make the forward-looking reports, most notably, without limit, which Helix danger issue wont lead to Helix’s real outcome or activities to differ materially through the forward-looking claims.

Forward-looking claims and critical information depend on the viewpoints, assumptions and objectives of Helix’s management about go out in this news launch, and Helix will not suppose any responsibility to upgrade any forward-looking record or help and advice should those viewpoints, assumptions or expectations, or additional scenarios changes, except as required for legal reasons.